logo
episode-header-image
Feb 2023
30m 11s

Episode 047: Myeloma Series, Pt.8- Myelo...

Rouleaux University Medical Center
About this episode
We continue our myeloma series, transitioning our discussion from autologous stem cell transplant to maintenance therapy for myeloma. Content: - Why do we use revlimid (lenalidomide) maintenance? - What about in high risk patients? - What is the role of MRD testing? - What about daratumumab in the maintenance setting? This episode has been sponsored by Pr ... Show More
Up next
Oct 21
Episode 168: Pancreatic Cancer Series, Pt. 3 – Borderline Resectable and Locally Advanced Disease
This week we continue our Pancreatic Cancer series with the two middle categories of non-metastatic disease: borderline resectable and locally advanced. Using the case of a 61-year-old woman with a pancreatic body mass abutting the superior mesenteric artery, we walk through the ... Show More
30m 49s
Oct 14
Episode 167: Pancreatic Cancer Series, Pt. 2 – Resectable Disease
This week our pancreatic cancer series moves from diagnosis to management, starting with resectable disease. Using the case of a 68-year-old man with a 2.8 cm adenocarcinoma of the pancreatic head, we define what "resectable" actually means, review the operation and the goal of a ... Show More
26m 23s
Oct 7
Episode 166: Pancreatic Cancer Series, Pt. 1 – Biology, Diagnosis, and Staging
This week we kick off a brand-new series on pancreatic cancer, starting with the fundamentals. Using the case of a 68-year-old man with painless jaundice, weight loss, and new-onset diabetes, we cover the epidemiology and sobering survival statistics of pancreatic ductal adenocar ... Show More
28m 52s
Recommended Episodes
May 2022
S1 Episode 2: Frontline Therapy for Multiple Myeloma
Joseph Mikhael, MD, and Peter Voorhees, MD, discuss frontline therapy for multiple myeloma and new options for both transplant-eligible and transplant-ineligible patients. Relevant disclosures can be found with the episode show notes on Medscape.com (https://www.medscape.com/view ... Show More
23m 37s
May 2023
Multiple Myeloma
<p>This week’s episode is part 2 of our plasma cell dyscrasias series. We will go over the important details on risk stratification, as well as initial and relapse treatment options for Multiple Myeloma, with key details on the pharmacology of myeloma drugs.</p><p><br/></p> 
16m 47s
Jul 2019
Myeloma
<p>In this episode I cover myeloma.<br/><br/>If you want to follow along with written notes on myeloma go to <a href='https://zerotofinals.com/medicine/haematology/myeloma/'>zerotofinals.com/medicine/haematology/myeloma/</a> or the haematology section in the Zero to Finals medici ... Show More
14m 52s
Sep 2025
S2 Episode 3: When Is the Best Time to Use CAR T-Cell Therapy in Multiple Myeloma?
Joseph Mikhael, MD, and Krina K. Patel, MD, MSc, discuss considerations for CAR T-Cell therapy in multiple myeloma, including age, access, and bridging therapy. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.com/viewarticle/1002715. ... Show More
24m 38s
Aug 2025
S2 Episode 1: Managing Side Effects and Maximizing Quality of Life in Multiple Myeloma Patients
Joseph Mikhael, MD, and Surbhi Sidana, MD, discuss the importance of balancing treatment intervals, managing side effects, and maximizing quality of life in multiple myeloma patients. Relevant disclosures can be found with the episode show notes on Medscape https://www.medscape.c ... Show More
23m 58s
Dec 2024
Primary resistance to BCMA-targeted bispecifics in multiple myeloma, emapalumab therapy in hemophagocytic lymphohistiocytosis, and chemotherapy-induced pyroptosis as a mechanism of thrombus formation
In this week's episode, we’ll learn more about mechanisms of primary resistance to BCMA-targeted bispecific T-cell engagers in relapsed/refractory multiple myeloma, the effects of emapalumab therapy on outcomes in patients with pediatric hemophagocytic lymphohistiocytosis who rec ... Show More
20m 5s
Jul 2020
Chapter 11: Hematology and Oncology (Part 7)
In the final episode from the Hematology and Oncology chapter of Crush Step 1, we discuss: - Myeloproliferative Disorders - Disorders of Heme Production - Pharmacologic Treatment Learn more about your ad choices. Visit megaphone.fm/adchoices 
50m 21s
Jul 2020
Chapter 11: Hematology and Oncology (Part 5)
In this episode from the Hematology and Oncology chapter of Crush Step 1, we continue the discussion of pathology covering: - Clotting Factor Deficiencies - Hereditary Thrombosis Syndromes - White Blood Cell Neoplastic Proliferation (Leukemias and Lymphomas) Learn more about your ... Show More
43m 46s
Aug 2025
IPI/NIVO for mCRC with Dr. Sharlene Gill
In this episode of MedOncNow, Dr. Sharlene Gill takes us through the evolving changes in the treatment of dMMR/MSI-H mCRC. Given that BMS has a company-sponsored PSP program, I felt it timely to discuss how Ipilimumab and Nivolumab fits into our treatment strategy. 
33m 23s
May 2022
Acute Myeloid Leukemia (AML)
<p>Today’s episode is all about AML (acute myeloid leukemia), including the usual presentation, diagnostic work-up, risk stratification (and tricks to remember these), molecular testing, and treatment options for first-line, as well as relapsed/refractory disease.</p> 
15m 18s